Clinical data | |
---|---|
Trade names | Lanvis, Tabloid, others |
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a682099 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 30% (range 14% to 46%) |
Metabolism | Intracellular |
Elimination half-life | 80 minutes (range 25–240 minutes) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.299 |
Chemical and physical data | |
Formula | C5H5N5S |
Molar mass | 167.19 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Tioguanine, also known as thioguanine or 6-thioguanine (6-TG) or tabloid is a medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myeloid leukemia (CML).[2] Long-term use is not recommended.[2] It is given by mouth.[2]
Common side effects include bone marrow suppression, liver problems and inflammation of the mouth.[2][3] It is recommended that liver enzymes be checked weekly when on the medication.[2] People with a genetic deficiency in thiopurine S-methyltransferase are at higher risk of side effects.[3] Avoiding pregnancy when on the medication is recommended.[2] Tioguanine is in the antimetabolite family of medications.[3] It is a purine analogue of guanine and works by disrupting DNA and RNA.[4]
Tioguanine was developed between 1949 and 1951.[5][6] It is on the World Health Organization's List of Essential Medicines.[7]